Columbia University Medical Center to evaluate Biocept's Target Selector platform to
Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company's Target Selectorâ„¢ platform to diagnose leptomeningeal metastases (LM) in patients with breast cancer.
More... |
All times are GMT -7. The time now is 03:55 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021